Q3 EPS Estimates for Revolution Medicines Reduced by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities researchers at Wedbush reduced their Q3 2025 earnings estimates for Revolution Medicines in a research report issued on Thursday, September 11th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($1.33) for the quarter, down from their prior estimate of $0.02. Wedbush currently has a “Outperform” rating and a $77.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.14) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.43) EPS, Q3 2026 earnings at ($1.46) EPS, Q4 2026 earnings at ($1.48) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($5.52) EPS and FY2028 earnings at ($3.67) EPS.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.37). During the same quarter in the previous year, the firm posted ($0.81) EPS. The business’s revenue was up .0% on a year-over-year basis.

Several other brokerages have also recently issued reports on RVMD. Guggenheim restated a “buy” rating and issued a $80.00 target price on shares of Revolution Medicines in a report on Wednesday, June 25th. The Goldman Sachs Group raised their target price on shares of Revolution Medicines from $65.00 to $73.00 and gave the stock a “buy” rating in a report on Friday. Raymond James Financial initiated coverage on shares of Revolution Medicines in a report on Friday. They issued a “strong-buy” rating and a $72.00 target price on the stock. Lifesci Capital initiated coverage on shares of Revolution Medicines in a research report on Monday, August 18th. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, Piper Sandler initiated coverage on shares of Revolution Medicines in a research report on Monday, August 18th. They issued an “overweight” rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and fourteen have assigned a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $73.67.

Revolution Medicines Trading Up 0.7%

Shares of RVMD stock opened at $46.55 on Monday. Revolution Medicines has a 12-month low of $29.17 and a 12-month high of $62.40. The company has a current ratio of 11.79, a quick ratio of 11.79 and a debt-to-equity ratio of 0.13. The firm’s 50 day moving average is $37.94 and its 200 day moving average is $38.17. The stock has a market capitalization of $8.70 billion, a P/E ratio of -10.34 and a beta of 1.12.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 5,238 shares of Revolution Medicines stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $40.17, for a total value of $210,410.46. Following the sale, the chief financial officer directly owned 113,314 shares in the company, valued at approximately $4,551,823.38. The trade was a 4.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 8.20% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in RVMD. CWM LLC boosted its stake in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after purchasing an additional 579 shares during the period. Banque Transatlantique SA bought a new position in Revolution Medicines in the 1st quarter worth about $42,000. Quarry LP purchased a new stake in shares of Revolution Medicines in the 1st quarter worth approximately $50,000. Twin Tree Management LP purchased a new stake in shares of Revolution Medicines in the 1st quarter worth approximately $58,000. Finally, a16z Perennial Management L.P. purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth approximately $67,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.